Creative Biolabs offers a full range of contract research services to biopharmaceutical organizations and university institutes to effectively develop and advance live biotherapeutics research. In each collaboration, we will apply our innovative spirit, deep expertise, abundant resources, and unparalleled support to create the best products and services for our fellow scientists.
The use of BEVs for biomedical applications has become a new trend. BEVs derived from cell membranes can transport various bioactive molecules to recipient cells, thereby altering the physiology of these cells. BEVs have been widely studied as biotherapeutic drugs due to their drug-loading ability, immune stimulation ability, and easy modification. BEVs are non-replicable and safer to use than their parent bacteria, especially since they are non-infectious and have a better safety rating. All bacteria release extracellular vesicles (EVs) as a mechanism of communication between species. BEVs are spherical lipid bilayer nanostructures, ranging from 20 to 300 nm in size. They are produced by Gram-negative and Gram-positive bacteria. The composition and content of BEVs originate in the producer strain and differ depending on the growth phase and conditions.
Fig.1 Schematic picture summarizing the immunomodulatory effects elicited by microbiota-derived BEVs in the gut. (Díaz, 2021)
Creative Biolabs can prepare commensal and probiotic-derived EVs according to your project requirements to study their role in health and disease, such as immune regulation, as well as their role as a key mediator of bacteria-host interactions in the gut. Including but not limited to the following bacteria-derived-EVs:
Nano-BEVs have great potential as a new drug delivery vector because they can accommodate and deliver a variety of bioactive molecules. EVs secreted by bacteria provide a variety of ingenious synergies for biomedical applications. Because of its proven immunomodulatory properties, BEV has been used as a viable tool for drug delivery, vaccine development, disease diagnosis, and more. BEV is considered a promising new therapy. Engineered BEVs are being developed as new vaccines and adjuvants for emerging and new diseases or as specialized drug delivery vehicles.
Using EV as a drug delivery system can offer several advantages, including its nanosize, biocompatibility (low toxicity) compared to synthetic drug delivery systems, ability to cross biological barriers, ability to protect its delivery from adverse environmental conditions (pH, enzymes, oxidative stress), and the possibility of modifying parent cells to modify EV composition.
Fig.2 Biological advantages and potential use of probiotic-derived EVs. (Rubio, 2022)
Creative Biolabs has extensive and deep knowledge and experience in the probiotic field. If you would like more details about our lab-scale production services or would like to consult our experts, please feel free to contact us.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.